Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

Bullboard Posts

Comment by robertshawon Oct 16, 2017 9:41am

153 Views

Post# 26815900

RE:RE:This week 180

LaserStock29 wrote: Id like to congratulate Patient 3 YES 3!! on their 180 day examination. Hopefully it is today and it goes really well.

Q4 is the biggest quarter for Theralase

Treatment ; Last of 5 (TBD) 'November??'

Addition of another Indication : (Q4) We're thinking GBM

Phase 2 decision; Predicated upon Phase 1b Safety & Tolerability data equates to 1 month CT scans

-I find this the most undertalked point on this forum.

-I also find it extremely smart of PMH to have treated Patient 4 to stagger him for this week right after patient 3 so that a cystoscope can be done on at least one high dose patient before applying for Phase 2 trials. This only makes the data set strength even more compelling.

So we are gonna find out if Roger has been negotiating on our behalves with a JV about Phase 2 and beyond, whether the widening of the pipeline has a purpose to be illuminated in Q4 before the X-Mas holidays.

So if anyone is confused.. Phase 1b trials are safety and tolerability

All data gathered is of that nature and is the sole basis of which Phase 2 trials are granted..

You cannot say oh this is a special trial and we need efficacy data.. no no no that's not how this works

Long story short.. the second we have treated the last of 5.. start that 30 day countdown.. cause the CT scan will begin the process of Phase 2 approval.

LaserStock29 wrote:
Patient P1-P3 (Low dose)

Sept 26
Oct 9
Oct 16 (DONE TODAY!!)

Patient 4 (High dose)

Oct 17

(Or at the worst.. sometime this week for both.. then u gotta figure the 23rd Monday for the report.

You also have to figure that Patients 5 & 6 were treated and had their 1 month CT scan.

That's vital information because the data set can read for this report

3 Low dose 180 day exit

1 High dose cystoscope + 2 One month CT (CT's confirm full safety/tolerability pharmokinetics)

Which that information is enough to get us to Phase 2 most technically speaking.

heres a few options far as I can see iit.

1. JV and a valuation to hopefully Nasdaq $4 (basically what we all want for the first 'premium level up for what a clinical company should be' )

2. We meet Doug Loes .90c mark for 3/3 data

3. Pop and Warrant flush and we stay at sub .50

4. Straight out savage PP and gut us again.

Best of luck to us... This ishould be our moment